Highlights from #ASCO25; Biotech’s icy market; Sanofi’s $9B acquisition; and...
Happy Saturday, dear readers! It’s another edition of Endpoints Weekly, your one-stop shop for all of the week’s biggest biopharma news. So grab a cup of your favorite morning blend and let’s jump into...
View ArticleSanofi speeds up global shipping for Beyfortus as RSV antibody market set to...
Sanofi on Monday said it plans to deliver its AstraZeneca-partnered RSV product Beyfortus “well ahead” of the disease season that starts in November to meet growing demand for its prophylactic...
View ArticleWho are the women reshaping biopharma R&D? Nominate them for Endpoints'...
Today we’re opening nominations for our seventh annual Women in Biopharma R&D special report via this form. Over the years, we’ve honored more than 120 women who have left their mark ...
View ArticleMetsera shares early data on anti-obesity amylin candidate
Metsera, which is attempting to make long-acting obesity and metabolic disease medicines, has shared its first clinical data as a recently minted public company. The New York-based biotech said Monday...
View ArticleAvidity to seek accelerated approval for FSHD drug; Axsome to run another trial
Plus, news about Mosanna Therapeutics, Concentra Biosciences, Elevation Oncology, Keros, TuHURA Biosciences and PolyPid: Avidity Biosciences says FDA is open to accelerated approval for FSHD drug: The...
View ArticleNewAmsterdam's experimental cholesterol drug reduces presence of Alzheimer's...
NewAmsterdam Pharma’s stock ticked upward on Monday after a biomarker analysis of its experimental cholesterol-lowering drug showed promise in Alzheimer’s disease. The drug, a CETP inhibitor known as...
View ArticleMerck unveils Phase 3 data for oral PCSK9 inhibitor enlicitide decanoate
Merck’s drug candidate for high cholesterol has succeeded in two late-stage trials in different groups of patients, a milestone the company says should bring it a step closer to launching the first...
View ArticleFederally-funded cancer research comes to a perilous crossroads
Paul Nghiem and the physician-scientists who make up the Merkel Cell Carcinoma Collaborative (MC3) Institute have a lot riding on an upcoming decision at the National Cancer Institute about their $15.7...
View ArticleTwist Bioscience urges Trump administration for tariffs on synthetic DNA
While many major pharmas are speaking out against the threat of tariffs on their industry, one company is urging the government to increase taxes on imported synthetic DNA. Twist Bioscience CEO Emily ...
View ArticleFDA approves Merck's RSV antibody drug for babies
The FDA approved Merck’s RSV antibody for babies, teeing up a rivalry with Sanofi and AstraZeneca’s Beyfortus. The decision adds a new entrant to the RSV prevention space for the youngest kids, and...
View ArticleFDA limits stomach, esophageal cancer labels for Merck's Keytruda, Bristol...
The FDA late last month sent letters to Merck and Bristol Myers Squibb telling them that their blockbuster cancer drugs Keytruda and Opdivo should be limited to metastatic gastric, gastroesophageal...
View ArticleFormer HHS lawyer criticizes politicization of Novavax vaccine decision
The FDA's infusion of a political appointee into the approval decision for Novavax's Covid-19 vaccine "imperils public health and innovation," former HHS employees and others wrote in a JAMA viewpoint...
View ArticleFDA reinstates generic drug policy group let go in April firings
The FDA has reinstated a generic drug policy team that was laid off in April, one that was at least partially responsible for leading the agency to a record number of new generic drug approvals ...
View ArticleNational Resilience to shutter six manufacturing sites amid biotech slowdown
The venture-backed drug manufacturing company National Resilience said it will close six underutilized sites in a significant reset of its ambitions to grow into a major player in biopharmaceutical...
View ArticleTrump administration removes all members of CDC vaccine board
HHS Secretary Robert F. Kennedy Jr. removed all members of the CDC’s vaccine advisory panel, known as the Advisory Committee on Immunization Practices, an extraordinary move to gut years of vaccine...
View ArticleOdyssey Therapeutics withdraws IPO plans as public markets remain frozen
Immunology biotech Odyssey Therapeutics has withdrawn its plans to go public via an IPO, according to a regulatory filing on Monday evening. The biotech didn't appear to immediately need the cash....
View ArticleRecursion to lay off 20% of staff, a month after slashing its pipeline
Recursion, one of the original AI-driven biotech companies that merged with its peer Exscientia last year, is laying off about 20% of its employees. The Salt Lake City-based biotech disclosed the job...
View ArticleExclusive: Post-Lilly deal, Scorpion crew carries on with $177M at Antares
BOSTON – Antares Therapeutics is in a unique position. The Boston and South San Francisco biotech said Tuesday it's raised a $177 million Series A, but it's much further along than most drug developers...
View ArticleFormer a16z biotech investment leader Vijay Pande exits the VC firm
Vijay Pande is leaving Andreessen Horowitz after 11 years at the VC firm, he wrote in Monday evening posts on LinkedIn and X. His departure comes six months after he was ...
View ArticleGoodRx goes toe-to-toe with Hims, Ro as it pushes into ED treatment
GoodRx, the company that offers drug discounts at the pharmacy counter, now wants to help patients tackle erectile dysfunction. The company on Tuesday said it’s offering subscriptions that include a...
View Article